• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022 –2031
ConclusionsCVD in people with type 2 diabetes will substantially impact the Australian healthcare system and society over the next decade. Future work to investigate different strategies to optimize the control of risk factors for the prevention and treatment of CVD in type 2 diabetes in Australia is warranted.
Source: PharmacoEconomics - March 21, 2023 Category: Health Management Source Type: research

Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia.
CONCLUSIONS: Applying a cross-sectorial government perspective budget impact assessment improves our understanding of fiscal changes attributed to ASCVD based on changes in premature mortality and work activity and how this influences lifetime tax contributions and public benefits. The main cost driver observed was associated with reduced ASCVD events that enabled people to remain productive and paying taxes. PMID: 33464137 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 20, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions
ConclusionReclassifying OCPs is likely to be considered cost effective by Australian decision makers.
Source: PharmacoEconomics - May 8, 2019 Category: Health Management Source Type: research